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Background: Several novel oral anticoagulants have been studied for the prevention and treatment of
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scenarios in which they must choose among these and conventional anticoagulants for the treatment of
this potentially fatal condition.
Objective: To review the results of Phase III clinical trials that investigated the novel oral anticoagulants
for the treatment of deep vein thrombosis and pulmonary embolism. Potential advantages and
disadvantages of these anticoagulant agents with respect to each other and conventional therapy will
also be explored through a case-based approach.
Methods: A literature search in PubMed was conducted that identiﬁed Phase III clinical trials investigat-
ing the novel oral anticoagulant agents for the treatment of VTE.
Results: The new oral anticoagulant agents have been shown to be as safe and effective for the treatment
of VTE as conventional therapies.
Conclusions: These novel, oral anticoagulant agents are legitimate options for the treatment of VTE.
A careful assessment of a patient's comorbidities, medication use, and laboratory results should be
undertaken before prescribing the new oral anticoagulant agents for patients with VTE.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Several novel, oral anticoagulant agents have been studied for
the prevention and treatment of venous thromboembolism (VTE).
The purpose of this article is to review the results of Phase III
clinical trials that investigated these medications for the treatment
of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Potential advantages and disadvantages of these anticoagulant
agents with respect to each other and conventional therapy will
also be explored through a case-based approach.Pharmacologic Proﬁle
The pharmacologic proﬁle of the new oral anticoagulants is
summarized in Table 1. These medications share similar proper-
ties, such as quick onset of action, interactions with the
P-glycoprotein pathway, and renal excretion. All of the Phase III
clinical trials excluded patients with severe renal insufﬁciency,r Inc. This is an open access article u
artment of Surgery, Jefferson
efferson University Hospitals,
, PA 19107.
nis).including the dialysis population. Unlike the factor Xa inhibitors,
dabigatran is neither a substrate nor an inhibitor/inducer of the
cytochrome P450 system. Because of its lower protein binding,
dabigatran is partially dialyzable, whereas the other anticoagu-
lants cannot be eliminated via this mechanism. There is no
currently available antidote for any of these medications and the
reversal of their anticoagulant effects with products such as
prothrombin complex concentrate and fresh frozen plasma has
been minimally investigated.1 Furthermore, there are no validated
tests to monitor the anticoagulant effects of these medications
because they were speciﬁcally studied in Phase III trials without
the need to perform routine monitoring. The thrombin clotting
time, ecarin clotting time, and activated partial thromboplastin
time are most affected by dabigatran and may be useful for ruling
out the presence or absence of its anticoagulant effect.2 Apixaban,
rivaroxaban, and edoxaban prolong the prothrombin time to a
greater extent than the activated partial thromboplastin time.3,4
As will be shown below, the trials investigating these anticoagu-
lants for the treatment of VTE are divided into 2 basic groups. In
the acute VTE studies, the novel anticoagulants were compared
with standard therapy in patients with a new VTE who were not
being treated with any anticoagulation at the time of the diagnosis.nder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Pharmacologic proﬁle of the new oral anticoagulants.
Variable Apixaban Dabigatran etexilate* Rivaroxaban Edoxaban
Target Factor Xa Factor IIa (thrombin) Factor Xa Factor Xa
Bioavailability (%) 50 7 10 mg dose: 80–100 60
20 mg dose: 66 (increases with food)
Time to peak onset (h) 3–4 1 2–4 1–2
Half-life (h) 12 12–17 5–9 8–10
Metabolism 25% Hepatic (CYP3A4) 20% Conjugation 50% Hepatic (CYP3A4/5, CYP212) 30% (Hydrolysis, CYP3A4)
75% Unchanged 80% Unchanged 50% Unchanged 70% Unchanged
Elimination 25% Renal 80% Renal 66% Renal 35% Urine
75% Intestinal 80% Intestinal 28% Intestinal 65% Intestinal
P-glycoprotein interaction† Yes Yes Yes Yes
Cytochrome P450 interaction Yes No Yes Yes
Coagulation tests most affected PT/INR, anti-factor Xa activity aPTT, ECT, TT PT/INR, anti-factor Xa activity PT/INR, anti-factor Xa activity
Dialyzable No Yes (60% No No
Antidote No No No No
aPTT ¼ activated partial thromboplastin time; ECT ¼ ecarin clotting time; PT/INR ¼ prothrombin time/international normalized ratio; TT ¼ thrombin clotting time.
n Dabigatran etexilate is hydrolyzed by hepatic and plasma esterases to dabigatran.
† The P-glycoprotein (P-gp) system prevents the absorption or enhances the secretion of certain medications known as P-gp substrates. Inhibition of this system
increases the drug levels of P-gp substrates whereas its induction decreases drug levels. Apixaban, dabigatran, and rivaroxaban are P-gp substrates.
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least a 3-month duration of treatment for a VTE were randomized
to various therapies.Clinical Trial Results for Acute VTE
Rivaroxaban
Two trials investigated the use of rivaroxaban for the treatment
of VTE. The Einstein-Acute DVT study was an open-label, random-
ized, event-driven, noninferiority trial comparing rivaroxaban (15
mg twice daily for the ﬁrst 3 weeks followed by 20 mg once daily)
to conventional anticoagulation therapy, which consisted of a low-
molecular-weight heparin followed by a vitamin K antagonist, in
patients with a proximal DVT without PE.5 Patients with a
creatinine clearance o30 mL/min, clinically signiﬁcant liver dis-
ease, or severe hypertension were excluded. The use of a throm-
bectomy procedure, a vena cava ﬁlter, or ﬁbrinolytic agents
rendered patients ineligible for the trial. Concomitant use of strong
cytochrome P450 inhibitors (ie, protease inhibitors or systemic
ketoconazole) or inducers (ie, rifampicin, carbamazepine, and
phenytoin) were also reasons for exclusion. The use of nonster-
oidal anti-inﬂammatory agents or antiplatelet medications was
allowed although discouraged. Speciﬁcally, aspirin up to a total
daily dose of 100 mg, clopidogrel 75 mg/d, or both were permitted.
The majority of patients were treated for 6 to 12 months. The
primary efﬁcacy outcome was symptomatic, recurrent VTE
(including fatal PE), whereas the main safety measure was the
combination of major or clinically relevant nonmajor bleeding. As
shown in Table 2, rivaroxaban was as effective as standard therapy
in preventing recurrent VTE with a similar safety proﬁle.
Only 12% to 13% of patients in this study were older than age 75
years. Patients with a creatinine clearance of 30 mL/min were
excluded; however, only 7% to 8% of patients had a creatinine
clearance between 30 and 50 mL/min.5 Unlike the Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin
K Antagonism for Prevention of Stroke and Embolism Trial in AtrialFibrillation (ROCKET-AF) study in which patients with a creatinine
clearance between 30 and 50 mL/min were given a reduced dose
of rivaroxaban 15 mg once daily, all patients in the Einstein-DVT
study received the 20 mg daily dose regardless of kidney function.
Sixty-eight percent to 70% of patients were considered to have an
extensive thrombus burden. There were no differences in the
efﬁcacy outcome in the subgroups analysis according to the
type of thrombotic event (idiopathic vs provoked), presence of
thrombophilia or malignancy, or extent of thrombus burden.
Rivaroxaban was not associated with an increase in risk of vascular
events, changes in liver function tests, or premature discontinua-
tion of study drug compared with standard therapy.
The Einstein-PE trial was an open-label, event-driven, non-
inferiority study with a similar design to the Einstein-acute DVT
trial comparing rivaroxaban with standard therapy in patients
with a PE (with or without a DVT). The principal efﬁcacy outcome
and safety measure were the same as in the Einstein-DVT trial.6
The majority of patients were treated for 6 to 12 months. A dose-
conﬁrmation phase was performed in which the ﬁrst 400 patients
underwent repeat lung imaging at the end of the ﬁrst 3 weeks of
treatment to exclude asymptomatic deterioration. There was no
difference in the efﬁcacy outcome at the end of the ﬁrst 21 days of
therapy. Overall, rivaroxaban was found to be as effective and safe
as standard therapy in preventing recurrent VTE. Signiﬁcantly less
major bleeding occurred in patients treated with rivaroxaban.
Approximately 24% to 25% of patients in the trial were considered
to have extensive thrombus burden as deﬁned by the involvement
of multiple lobes and 425% of the entire pulmonary vasculature.
There were no differences in the efﬁcacy outcome according to
thrombus burden or type of index event. There were also no
differences in changes of liver function parameters, coronary
events, or premature discontinuation of study drug between the
groups.
A pooled analysis of the Einstein trials was recently published7
that veriﬁed the noninferiority of rivaroxaban compared with
vitamin K antagonism. That analysis also revealed a statistically
signiﬁcant reduction in major bleeding in patients exposed to this
anti-Xa inhibitor compared with the conventional anticoagulation
Table 2
Clinical trials comparing the new oral anticoagulants with standard therapy in acute venous thromboembolism.*
Variable Einstein-DVT Einstein-PE AMPLIFY€ RE-COVER RE-COVER II Hokusai-VTE
Trial design Open-label,
randomized
Open-label,
randomized
Double-blind,
randomized
Double-blind,
randomized
Double-blind,
randomized
Double-blind, randomized
Regimen Rivaroxaban 15 mg
BID  3 wk,
then 20 mg daily
Rivaroxaban 15 mg
BID  3 wk, then
20 mg daily
Apixaban 10 mg BID
 7 d, then 5 mg
BID
Standard therapy
for median 9 d,
then dabigatran
150 mg BID
Standard therapy
for median 9 d,
then dabigatran
150 mg BID
Standard therapy for median
7 d, then edoxaban 60 mg
daily (30 mg daily if CrCL 30–50
mL/min or weight r60 kg
Average age (y) 55–58 58 57 54–55 55 56
PE only (%) — All patients 25 21 23 30
DVT þ PE (%) All patients (no PE) 25 8–9 10 8–9 10
Unprovoked
VTE (%)
61–63 64–65 90 Undeﬁned Undeﬁned 65–66
Prior VTE (%) 19 19–20 15–17 25–26 16–19 65–66
Malignancy (%) 5–7 5 3 5 4 9
Thrombophilia (%) 6–7 5–6 2–3 Undeﬁned Undeﬁned Undeﬁned
%TTR for INR† (%) 57.7 62.7 61 60 57 63.5%
Efﬁcacy outcome‡ Rivaroxaban: 2.1% Rivaroxaban: 2.1% Apixaban: 2.3% Dabigatran: 2.4% Dabigatran: 2.3% Edoxaban: 3.2%
Standard Tx: 3.0% Standard Tx: 1.8% Standard Tx: 2.7% Standard Tx: 2.1% Standard Tx: 2.2% Standard Tx: 3.5%
Major bleeding§ Rivaroxaban: 0.8% Rivaroxaban: 1.1% Apixaban: 0.6% Dabigatran: 1.6% Dabigatran: 1.2% Edoxaban: 1.4%
Standard Tx: 1.2% Standard Tx: 1.2% Standard Tx: 1.8% Standard Tx: 1.9% Standard Tx: 1.7% Standard Tx: 1.6%
Clinically relevant
bleeding||
Rivaroxaban: 8.1% Rivaroxaban: 10.3% Apixaban: 4.3% Dabigatran: 5.6% Dabigatran: 5.0% Edoxaban: 8.5%
Standard Tx: 8.1% Standard Tx: 11.4% Standard Tx: 9.7% Standard Tx: 8.8% Standard Tx: 7.9% Standard Tx: 10.3%
CrCL ¼ creatinine clearance; DVT ¼ deep vein thrombosis; INR ¼ international normalized ratio; PE ¼ pulmonary embolism; TTR ¼ time in therapeutic range;
Tx ¼ treatment.
n Standard therapy is deﬁned as the use of short-acting anticoagulant agent (ie, intravenous heparin, low–molecular-weight heparin) followed by a vitamin K antagonist.
† TTR for vitamin K antagonism.
‡ Symptomatic VTE and VTE-related death.
§ Major bleeding is deﬁned per the International Society of Thromobosis and Haemostasis guidelines.
|| Clinically relevant bleeding is deﬁned as the composite of major and clinically relevant nonmajor bleeding per the International Society of Thrombosis and Haemostasis
guidelines.
€ Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy.
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malignancy, and large thrombus burden as well as a history of
recurrent VTE revealed similar efﬁcacy and safety proﬁles.Apixaban
The Apixaban for the Initial Management of Pulmonary Embo-
lism and Deep Vein Thrombosis as First-Line Therapy (AMPLIFY)
trial was a randomized, double-bind study comparing apixaban
(10 mg twice daily for the ﬁrst 7 days followed by 5 mg twice
daily) to standard therapy (low–molecular-weight heparin fol-
lowed by warfarin) for 6 months in patients with a proximal deep
vein thrombosis and/or pulmonary embolism.8 The primary efﬁ-
cacy end point was the composite of symptomatic recurrent VTE or
VTE-related death, whereas the main safety outcome was major
bleeding. Notably, patients with a provoked VTE without the
existence of a persistent risk factor and patients with cancer
whose treatment plan included 6 months or more of low–
molecular-weight heparin were excluded. Patients who under-
went neurosurgery or experienced an ischemic stroke within a
week of randomization; experienced head trauma or major sur-
gery within 2 months; or experienced intracranial, intraocular, or
gastrointestinal bleeding within 6 months were deemed ineligible.
As in the Einstein trials, patients undergoing a thrombectomy,
insertion of a caval ﬁlter, or exposure to a ﬁbrinolytic agent were
excluded. Patients with active liver disease or reduced renal
function (creatinine clearance o25 mL/min) were also notallowed to participate in the study. The use of dual antiplatelet
therapy or potent inhibitors of the cytochrome P450 system was
prohibited. Apixaban was found to be as effective as standard
therapy with signiﬁcantly less major bleeding. There were also no
differences in the rate of permanent drug discontinuation between
the treatment arms. Thirty-six percent to 38% of patients with a PE
were considered to have extensive thrombus burden.Dabigatran
The RE-COVER study was a randomized, double-blind, non-
inferiority trial comparing dabigatran 150 mg twice daily with
warfarin.9 Unlike the aforementioned studies, patients were
treated with a parental anticoagulant for a median of 9 days
before starting dabigatran. Patients with a PE associated with
hemodynamic instability or requiring thrombolytic therapy,
recent unstable cardiovascular disease, abnormal liver function,
and/or creatinine clearance o30 mL/min were excluded. Patients
taking up to 100 mg acetylsalicylic acid were allowed to partic-
ipate. The primary efﬁcacy outcome was deﬁned as the composite
of symptomatic VTE or VTE-associated death in the 6 months
after randomization. Several safety outcomes were investigated,
including bleeding events, acute coronary syndrome, other
adverse events, and results of hepatic function tests. Dabigatran
was found to be as effective and safe as standard therapy in
reducing recurrent VTE. There was a trend toward more gastro-
intestinal hemorrhage in patients treated with dabigatran. More
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event (P ¼ 0.05) and dyspepsia was more common in the
dabigatran group (P o 0.001). There were no major differences
in the rates of acute coronary events or abnormal liver function
tests between the groups. The RE-COVER II study had a similar
design and study end points to the original RE-COVER trial. As in
the original study, there was no difference between dabigatran
and warfarin in the composite of symptomatic VTE or VTE-related
death. Major bleeding occurred equally in both groups, whereas
dabigatran was associated with a statistically signiﬁcant decrease
in the composite of major or clinically relevant nonmajor bleed-
ing compared with vitamin K antagonism. A pooled analysis of
the RE-COVER trial results was also undertaken that showed no
difference in recurrent VTE or major bleeding between dabigatran
or warfarin. However, dabigatran was associated with signiﬁ-
cantly less major or clinically relevant nonmajor bleeding. Fur-
thermore, there were numerically more acute coronary
syndromes in patients treated with dabigatran, but this did not
reach statistical signiﬁcance.10Edoxaban
The Hokusai-VTE trail was a randomized, double-blind, non-
inferiority study comparing the effects of edoxaban 60 mg once
daily (or 30 mg once daily in patients with a creatinine clearance
30-50 mL/min or a body weight o60 kg) with warfarin in patients
with an acute VTE.11 The principal efﬁcacy outcome was the
incidence of symptomatic, recurrent VTE, whereas the principal
safety measure was the composite of major or clinically relevant
nonmajor bleeding (clinically relevant hemorrhage). Forty percent
of patients were diagnosed with a PE (with or without a DVT). As
in the RE-COVER trials, patients were treated with a standard
anticoagulant for at least 5 days before being exposed to the study
drug. A medium time of 7 days elapsed before the patients
assigned to the edoxaban group received the oral, anti-Xa inhib-
itor. Edoxaban was found to be noninferior to warfarin in prevent-
ing the primary efﬁcacy outcome, whereas it was superior to
vitamin K antagonism in reducing the risk of clinically relevant
bleeding (Table 2).Clinical Trial Results for Extended Treatment of VTE
Rivaroxaban
The Einstein Extension trial was a double-blind trial in which
patients with either a DVT or PE who were treated for at least
6 months with either standard therapy or rivaroxaban were
randomly assigned to continue treatment with rivaroxaban 20
mg daily or placebo.5 The exclusion criteria were the same as in
the Einstein acute DVT trial. The majority of patients were treated
for at least 6 months. The primary efﬁcacy outcome was sympto-
matic, recurrent VTE and the main safety measure was major
bleeding (as opposed to the Einstein DVT and PE trials, which
investigated the composite of major and clinically relevant non-
major bleeding as the main safety outcome). Rivaroxaban reduced
the rate of recurrent VTE by 82% (P o 0.001 for superiority) with a
nonsigniﬁcant increase in major bleeding. However, more patients
exposed to rivaroxaban experienced the composite of major or
clinically relevant nonmajor bleeding (P o 0.001). There were no
major differences in premature discontinuation of drug, vascular
events, or changes in liver function between study drug and
placebo.Apixaban
In the Apixaban after the Initial Management of Pulmonary
Embolism and Deep Vein Thrombosis with First-Line Therapy–
Extended Treatment (AMPLIFY-Extension) trial, 2 doses of apix-
aban (2.5 mg and 5 mg, twice daily) were compared with placebo
in patients who completed at least 6 months of anticoagulation for
either a DVT or PE.12 The main efﬁcacy outcome was deﬁned as the
composite of symptomatic recurrent VTE or death from any cause,
whereas the primary safety measure was major bleeding. The
exclusion criteria were similar to those of the AMPLIFY study.
However, patients with thrombophilia, multiple episodes of
unprovoked DVT or PE, or those taking potent P-glycoprotein
inhibitors were excluded from the extended treatment trial. Both
doses of apixabanwere found to be superior to placebo in reducing
the main efﬁcacy outcome. The rates of major bleeding as well as
the composite of major or clinically relevant nonmajor bleeding
were not statistically different.
Dabigatran
Two double-blind studies compared dabigatran 150 mg twice
daily with either warfarin (RE-MEDY, active–control) or placebo
(RE-SONATE, placebo–control) in patients who completed at least
3 months of treatment for VTE with an approved anticoagulant or
dabigatran in the RE-COVER trials.13 Participants in the active–
control study were treated for an average of 15.8 months, whereas
those enrolled in the placebo–control study were treated for
approximately 5.5 months on average. Patients considered to have
an increased risk of a recurrent VTE were enrolled in the RE-MEDY
study. The primary efﬁcacy outcome was symptomatic, recurrent
VTE in both trials. Unexplained death was also included in the
primary efﬁcacy outcome in the placebo–control study. Thrombo-
lytic therapy within 14 days before enrollment and patients with
inferior vena cava ﬁlters were not permitted to participate in the
active–control study. Patients with a malignancy were excluded
from the RE-SONATE trial.
Dabigatran was found to be as effective as warfarin and
superior to placebo for the efﬁcacy outcomes. However, numeri-
cally more patients experienced recurrent VTE in the active–
control study and the upper limit of the conﬁdence interval for
the hazard ratio approached the prespeciﬁed noninferiority
margin, which was criticized as being too large. There was a
trend toward less major bleeding with the direct thrombin
inhibitor compared with warfarin; however, signiﬁcantly fewer
patients treated with dabigatran experienced the composite of
major or clinically relevant bleeding events. Compared with
placebo, signiﬁcantly more clinically relevant bleeding events
occurred in patients exposed to dabigatran with no signiﬁcant
difference in major bleeding observed between these 2 groups.
Acute coronary syndrome occurred more frequently in those
patients exposed to direct thrombin inhibition in the active–
control study (P ¼ 0.02). However, statistically more patients
treated with dabigatran had coronary artery disease compared
with those treated with warfarin (8.4% vs 6.1%, respectively).
There was no difference in acute coronary syndrome between
recipients of dabigatran and placebo. Unlike the RE-COVER study,
there was no difference in the rate of drug discontinuation in
patients exposed to dabigatran in both the active–control and
placebo–control studies.Choosing the Ideal Anticoagulant
Although rivaroxaban and dabigatran are the only new oral
anticoagulants approved for the treatment of VTE, the therapeutic
Figure 1. Ultrasound image of calf veins with compression. Blue arrows indicate
dilated veins that do not compress, indicating the presence of a deep vein
thrombosis.
Figure 2. Chest computed tomography image. Blue arrows indicate ﬁlling defects
consistent with the presence of pulmonary embolism.
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the aforementioned trials. Furthermore, all of the anticoagulant
agents discussed in this article (with the exception of edoxaban) are
approved for the prevention of stroke in patients in nonvalvular
atrial ﬁbrillation. Clinicians will thus need to choose among these
options. Although no trial has directly compared these new med-
ications with one another, some of these agents may be more
preferable for certain patient populations based on their pharmaco-
logic proﬁles and results of the individual trials. The following cases
highlight the potential advantages and disadvantages of the new
oral anticoagulants with respect to each other and conventional
therapy in speciﬁc patient groups.
Case #1
A 52-year old man underwent an uneventful arthroscopic
repair of a torn right medial meniscus injury 1 month prior. He
presented with a chief complaint of right calf pain and swelling
that began within the past 48 hours. He takes no medications and
has no other medical conditions. On examination, he weighs 77 kg
and his vital signs are normal. He has 1þ right lower extremity
pitting edema extending from the ankle to the upper calf medially
along with calf tenderness on palpation. A lower extremity venous
Doppler ultrasound was performed and is shown in Figure 1. He
also underwent a laboratory assessment approximately 1 month
ago that revealed a creatinine clearance of 125 mL/min as
calculated by the Cockcroft-Gault formula along with a normal
blood count and liver function panel.
Discussion
As shown in Figure 1, both of the patient’s gastrocnemius veins
were dilated and noncompressible, consistent with a DVT in these
vessels without extension into the more proximal veins (ie, isolated
calf vein thrombosis [ICVT]). Patients with an ICVT were not studied
in the aforementioned clinical trials and there is a lack of large-scale
and well-designed clinical trials to address the question of whether
or not full dose anticoagulation is necessary in these patients. Given
the likely similar pathogenesis and risk factors for an ICVT and
proximal DVT, the results of the trials investigating the novel
anticoagulants can likely be extrapolated to the patient populationwith an ICVT. The American College of Chest Physicians guideline
suggests treating patients with an ICVT with full-dose anticoagula-
tion if they are symptomatic and/or have risk factors for thrombus
propagation (such as immobility or an active malignancy).14 Given
our patient’s symptoms and a relative reduction in his mobility
from his baseline, a decision was made to initiate full-dose anti-
coagulation therapy after conferring with his orthopedic surgeon.
As of now, only rivaroxaban and dabigatran are approved for the
treatment of an acute VTE. However, all of the new oral anti-
coagulants would likely be appropriate for this patient given his
young age, lack of comorbidities, normal renal function, and results
of the aforementioned trials. However, dabigatran as well as
edoxaban were not used as initial therapy in their respective trials
because patients were treated with a standard, parental antico-
agulant for at least 5 days before being exposed to these medi-
cations. On the other hand, apixaban and rivaroxaban were studied
for the initial treatment of VTE without the need to wait for at least
5 days before they were used. This difference in study design is
reﬂected in the Food and Drug Administration stipulation that a
parental anticoagulant be used for 5 to 10 days before starting
dabigatran for the treatment of an acute VTE. Thus, in addition to
the conventional anticoagulants, the other options for the treatment
of this patient is dabigatran 150 mg PO BID (after treating the
patient with low–molecular-weight heparin for 5-10 days as an
outpatient) or rivaroxaban 15 mg twice daily for the ﬁrst 3 weeks
and then 20 mg daily thereafter.
If, however, the same patient had a creatinine clearance of 40
mL/min, the risk/beneﬁt proﬁle may be different among the new
oral anticoagulants. As shown in Table 1, all of these medications
are renally excreted but to a different extent. Apixaban appears to
be associated with the least amount of renal excretion. There were
no differences in the efﬁcacy outcomes in the subgroup analysis
according to renal function of the new oral anticoagulants for the
treatment of VTE. A subgroup analysis for the safety outcomes in
patients with renal impairment was not provided for the RE-COVER
and RE-COVER II studies. Although there were no differences in the
bleeding outcomes in the subgroup analysis according to renal
function for the other anticoagulants, the medications with the least
amount of renal excretion, such as apixaban or rivaroxaban, may be
better options in patients with mild renal insufﬁciency given their
pharmacologic proﬁle. A recently published meta-regression anal-
ysis of the VTE and atrial ﬁbrillation clinical trials revealed a
Figure 3. Ultrasound image of common femoral vein with compression. Blue arrow
indicates a dilated and noncompressible vein with echogenic material consistent
with deep vein thrombosis.
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renal impairment whowere treated with apixaban or rivaroxaban.15
All patients with active liver disease were excluded from the
aforementioned trials. However, dabigatran is the only new anti-
coagulant that does not interact with the cytochrome P450 system.
This medication may thus be preferred over the others in patients
taking medications that have extensive hepatic metabolism or those
who may be exposed to such medications in the future, such as the
HIV population and those with a seizure disorder.
Case #2
A 62-year old man with a history of an unprovoked left popliteal
vein DVT 2 years ago presented with a chief complaint of a 1-week
history of dyspnea on exertion. His comorbidities include diabetes
mellitus (type 2), hypertension, and hyperlipidemia. He takes full-dose
aspirin, metformin, diovan, and insulin. On examination, his vital signs
are normal and he has 1þ left leg pitting edema with hemosiderin
deposition distally on his anterior shin. Otherwise, his examination is
unremarkable. His laboratory analysis is normal with the exception of
a minimally elevated troponin T level (0.04 ng/mL with an upper limit
of normal of 0.01 ng/mL). A computed tomography angiogram of
the chest was ordered and the images are shown in Figure 2.
An echocardiogram revealed normal right ventricular function.
Discussion
The patient was diagnosed with extensive bilateral PE. Due to
his elevation in troponin T level, his PE would be classiﬁed as
submassive given his normal hemodynamics. All of the new
anticoagulants have been studied in patients with PE. However,
exclusion criteria for all studies were the presence of hemody-
namic instability and the use of thrombolysis. Patients treated
with inferior vena cava ﬁlters were also excluded in the AMPLIFY,
Einstein, and Hokusai-VTE trials; however, thrombus burden was
described in these 3 studies but not in RE-COVER. Although
inconsistent, there is evidence that an abnormal vascular obstruc-
tion index, which is a reﬂection of the extent of thrombosis of the
vasculature, is associated with worse outcomes in patients with a
PE.16–19 Approximately one-quarter of patients in the Einstein-PE
trial were considered to have extensive thrombus burden based on
the anatomic distribution of ﬁlling defects. The ﬁrst 400 patients in
this trial were also screened for asymptomatic deterioration by
undergoing mandatory imaging after the ﬁrst 3 weeks of therapy.
Apixaban was also used in approximately one-third of patients
who were categorized as having an extensive thrombus burden.
Certain markers associated with right ventricular dysfunction,
such as an abnormal echocardiogram, computed tomography scan,
troponin or pro-B-type natriuretic peptide values, have been
associated with poorer outcomes in patients with a PE.20 Unlike
the apixaban and rivaroxaban studies, the Hokusai-VTE study also
published a subgroup analysis of its patients with a PE and
evidence of right ventricular strain as determined by an elevated
pro-B-type natriuretic peptide or a relative increase in the size of
the right ventricle compared with the left. In this subgroup of
participants, which accounted for approximately 30% of the study
population, fewer patients treated with edoxaban experienced the
primary efﬁcacy outcome compared with warfarin (3.3% vs 6.2%,
95% conﬁdence interval, 0.28–0.98). Unless more evidence surfaces
for the other anticoagulants, edoxaban, if approved, may be a more
appealing option in patients with a submassive PE. However, as
discussed above, a parental anticoagulant will likely need to be
used for the ﬁrst 5 to 10 days of treatment before patients begin
edoxaban.
Dabigatran, rivaroxaban, and apixaban have also been studied
in patients with acute coronary syndrome. However, all3 medications were associated with an increase in major or
clinically signiﬁcant bleeding when combined with antiplatelet
therapy in these trials.21–23 Dual antiplatelet therapy (with dose
limitations) was permitted in the Einstein trials, whereas aspirin
monotherapy (with dose limitations) was allowed in the AMPLIFY,
AMPLIFY-Ext, Hokusai-VTE, and RE-COVER trials. The use of anti-
platelet medications in the RE-MEDY and RE-SONATE studies was
not speciﬁed. With the exception of AMPLIFY-Ext and Hokusai-VTE
studies, in which 12% to 14% and 9% of patients were exposed to
aspirin, respectively, the percentage of patients also taking anti-
platelet medications in the VTE trials was not speciﬁed. Further-
more, the Hokusai-VTE trial was the only study that provided a
subgroup analysis for the safety outcomes according to the use of
antiplatelet therapy (which found no difference between edox-
aban and warfarin for major and clinically relevant nonmajor
bleeding). Based on the results of the acute coronary syndrome
trials (even though a different patient population was studied) and
historical data, which have shown an increase in major bleeding
when standard anticoagulation therapy was used with antiplatelet
medications, the new oral anticoagulants should be used cau-
tiously with antiplatelet drugs.
Dabigatran was associated with a higher rate of acute coronary
events compared with warfarin in the atrial ﬁbrillation study
(RE-LY).24 This ﬁnding was also seen in the extended treatment
study RE-MEDY (active–control) but not in RE-SONATE (placebo–
control) or the acute VTE study (RE-COVER). A meta-analysis of
several trials that compared this direct thrombin inhibitor with
different therapies, including placebo, found an increased risk of
acute coronary syndrome with dabigatran.25 The anti-Xa inhibitors
may thus be more preferable over dabigatran in patients with
coronary artery disease. In all of the atrial ﬁbrillation studies, the
reduction in stroke seen with the new oral anticoagulants was
primarily driven by a reduction in intracranial hemorrhage. How-
ever, dabigatran 150 mg twice daily was the only medication that
also signiﬁcantly reduced the risk of ischemic stroke.24,26,27 Dabi-
gatran may thus be preferable in this patient population.
Table 3
Clinical trials investigating the new oral anticoagulant agents for the extended treatment of venous thromboembolism (VTE)*
Variable Einstein-Ext AMPLIFY-Ext€ RE-MEDY RE-SONATE
Trial design Double-blind, randomized Double-blind, randomized Double-blind, randomized Double-blind, randomized
Regimen Rivaroxaban 20 mg daily vs
placebo
Apixaban 2.5 mg or 5 mg BID vs
placebo
Dabigatran 150 mg BID vs
warfarin
Dabigatran 150 mg BID vs
placebo
Average age (y) 58 56–57 54–55 56
Index event† (%) DVT: 60–64 DVT: 65–67 DVT: 65–66 DVT: 63–67
PE: 36–40 PE: 34–35 PE: 34–35 PE: 32
Unprovoked VTE (%) 73–74 91–93 Undeﬁned Undeﬁned
Prior VTE (%) 14–18 12–15 52–55 2 patients
Malignancy (%) 4–5 Excluded (3–4) 4 Excluded
Thrombophilia (%) 8 Excluded (1–2) 18 10–13
TTR for INR‡ (%) — — 65.3 —
Efﬁcacy outcome§ Rivaroxaban: 1.3% Apixaban 2.5 mg: 3.8% Dabigatran: 1.8% Dabigatran: 0.4%
Placebo: 7.1% Apixaban 5 mg: 4.2% Warfarin: 1.3% Placebo: 0%
Placebo: 11.6%
Major bleeding|| Rivaroxaban: 0.7% Apixaban 2.5 mg: 0.2% Dabigatran: 0.9% Dabigatran: 0.3%
Placebo: 0% Apixaban 5 mg: 0.1% Warfarin: 1.8% Placebo: 0%
Placebo: 0.5%
Clinically relevant
bleeding¶
Rivaroxaban: 6.0% Apixaban 2.5 mg: 3.2% Dabigatran: 5.6% Dabigatran: 5.3%
Placebo: 1.2% Apixaban 5 mg: 4.3% Warfarin: 10.2% Placebo: 1.8%
Placebo: 2.7%
DVT ¼ deep venous thrombosis; INR ¼ international normalized ratio; PE ¼ pulmonary embolism; TTR ¼ time in therapeutic range.
n Patients were treated with either a standard anticoagulant agent or study drug for at least 3 mo before being randomized into the extended treatment trials.
† DVT refers to DVT only, whereas PE could be PE with or without DVT.
‡ TTR for vitamin K antagonism.
§ Symptomatic VTE and VTE-related death.
|| Major bleeding is deﬁned per the International Society of Thromobosis and Haemostasis guidelines.
¶ Clinically relevant bleeding is deﬁned as the composite of major and clinically relevant nonmajor bleeding per the International Society of Thrombosis and Haemostasis
guidelines.
€ Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First- Line Therapy–Extended Treatment.
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A 45-year old manwith a medical history signiﬁcant for Crohn’s
disease presented with a 1-week history of left leg swelling. He
also had an unprovoked left femoral-popliteal vein thrombosis 15
years ago for which he received a 6-month duration course of
warfarin. He underwent a partial small bowel resection 1 month
prior for intractable abdominal pain. His medications are intra-
venous hydrocortisone and mesalamine. His examination is sig-
niﬁcant for 2þ left pitting edema in the pretibial region. His
laboratory workup is notable for a hemoglobin level of 6.7 g/dL.
The venous Doppler ultrasound of his left leg is shown in Figure 3.
Intravenous heparin was initiated and the primary medical service
inquired about the use of the new oral anticoagulants.Discussion
The patient is diagnosed with DVT of the common femoral vein
extending into his popliteal vein. His severe anemia was consid-
ered to be due to his active Crohn’s disease and recent surgery. The
use of the new oral anticoagulants would likely be considered
inappropriate for this patient. Although all of these medications
have short half-lives, they do not have an antidote and the reversal
of their anticoagulant effects has not been extensively studied. The
patient was unable to tolerate any food intake; thus, warfarin
should also likely be avoided. Low–molecular-weight heparin
likely best balances the risk/beneﬁt proﬁle for this patient given
its short half-life and partial reversibility.
Signiﬁcantly more patients who were exposed to dabigatran
experienced a gastrointestinal hemorrhage in the atrial ﬁbrillation
study (RE-LY) and there was a trend for more gastrointestinal
hemorrhage in the RE-COVER trial.9,24 Rivaroxaban was also
associated with a signiﬁcantly higher rate of gastrointestinal
bleeding events compared with warfarin in its atrial ﬁbrillation
study.27 A recent meta-analysis of the clinical trials in the atrialﬁbrillation population conﬁrmed a signiﬁcantly increased risk of
gastrointestinal hemorrhage with the novel anticoagulants com-
pared with vitamin K antagonism.28 However, apixaban was not
associated with this bleeding outcome in either the VTE or atrial
ﬁbrillation studies.26 This medication may thus be more appro-
priate in patients who have experienced a gastrointestinal hem-
orrhage or who are at risk for this complication. Dyspepsia was
signiﬁcantly more common in patients taking dabigatran in the
RE-LY and RE-COVER studies. Patients who may be predisposed to
his complication, such as those with irritable or inﬂammatory
bowel disease, peptic ulcer disease, or gastritis, may better tolerate
the anti-Xa inhibitors.
As noted in Tables 2 and 3, few patients with a malignancy or
hypercoagulable conditions were studied in the VTE trials. These
agents should thus be used cautiously in patients with active
cancer. However, dabigatran was investigated in 18% of patients
with thrombophilia in the extended treatment study and this may
be a feasible option for the extended treatment of VTE in this
patient population. Certain coagulation assays, including those
testing for activated protein C resistance, lupus anticoagulants, and
protein functional deﬁciencies may be falsely abnormal in patients
taking the new oral anticoagulants.3Conclusions
Until recently, the therapeutic options for the treatment of DVT
and PE have been limited. The approval of rivaroxaban and
dabigatran for the treatment of VTE, and the likely approval of
other anticoagulants, represents a paradigm shift in the treatment
of this potentially fatal condition. Although these medications
offer potential advantages over conventional therapy, careful
postmarketing surveillance will be required to establish their
efﬁcacy and safety in larger and more speciﬁc patient populations.
Elderly patients were underrepresented in all of the VTE trials—the
average age of patients studied for all of the trials was in the
T. Galanis et al. / Current Therapeutic Research 76 (2014) 76–83 83middle 50s. Although a recent, pooled analysis of the rivaroxaban
VTE trials did not show a difference in efﬁcacy or safety in patients
older than age 75 years, the effects of the new anticoagulants in
the elderly population, particularly outside of the setting of a
clinical trial, is not well established. Patients with multiple
comorbidities also appear to be underrepresented in these trials
and may be better suited to treatment with standard anticoagu-
lation. Noncompliant patients should not be prescribed the new
anticoagulant agents because of their short half-lives. As described
above, the efﬁcacy and safety of these new medications has not
been well established in patients with an active malignancy.
Despite a lack of head-to-head comparison trials, some of the
new oral anticoagulants may be better suited than others for
certain patient populations based on their pharmacologic proﬁles
and results of individual studies. Careful assessment of the risks
and beneﬁts of these new medications will remain essential in
ensuring that these drugs are implemented appropriately into
daily clinical practice.Acknowledgments
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